by rvvadmin | Apr 25, 2022 | 2022
TORONTO, April 25, 2022 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased...
by rvvadmin | Apr 18, 2022 | 2022
TORONTO, April 18, 2022 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, today...
by rvvadmin | Apr 11, 2022 | 2022
TORONTO, April 11, 2022 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased...
by rvvadmin | Mar 29, 2022 | 2022
Expected to seek DSMB approval to proceed with EUA application to the FDA in Q2-2022 Ongoing regulatory package activities for submission to international regulatory authorities for drug approvals TORONTO, March 29, 2022 – Revive Therapeutics Ltd. (“Revive” or...
by rvvadmin | Feb 24, 2022 | 2022
The naturally derived GMP psilocybin will be exported through distribution partner Mycrodose Therapeutics Inc. to the University of Wisconsin-Madison, Contract Research Organization for Revive Therapeutics VANCOUVER, BC, Feb. 24, 2022 – HAVN Life Sciences...
by rvvadmin | Feb 15, 2022 | 2022
TORONTO, Feb. 15, 2022 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to...
